Evidence map›Paper›PMID 26097006›Full record

ArticleChembiochem : a European journal of chemical biology2015

A Light-Controlled TLR4 Agonist and Selectable Activation of Cell Subpopulations.

Lalisa Stutts, Aaron P Esser-Kahn

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lalisa StuttsDepartment of Chemistry, University of California, 1102 Natural Sciences 2, Irvine, CA 92697-2025 (USA).
Aaron P Esser-KahnDepartment of Chemistry, University of California, 1102 Natural Sciences 2, Irvine, CA 92697-2025 (USA). aesserka@uci.edu.

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Directing The Immune System Via Polymeric Combinations of Molecular SignalsDP2AI112194 · NIAID · UNIVERSITY OF CHICAGO · PI ESSER-KAHN, AARON P · 2013 to 2013
$2.3M
NCI NIH HHS CA-62203NCI NIH HHS P30 CA062203NIAID NIH HHS DP2 AI112194NIAID NIH HHS DP2-AI112194
6 · The paper itself

Abstract

The spatial and temporal aspects of immune cell signaling are key parameters in defining the magnitude of an immune response. Toll-like receptors (TLRs) on innate immune cells are important in the early detection of pathogens and initiation of an immune response. Controlling the spatial and temporal signaling of TLRs would enable further study of immune synergies and assist in the development of new vaccines. Here, we show a light-based method for the spatial control of TLR4 signaling. A TLR4 agonist, pyrimido[5,4-b]indole, was protected with a cage at a position critical for receptor binding. This afforded a photocontrollable agonist that was inactive while caged, yet effected NF-κB activity in cells following UV photocontrolled deprotection. We demonstrated spatial control of NF-κB activation within a population of cells by treating all cells with the caged TLR4 agonist and constraining light exposure and consequent activation to a region of interest.

Indexed as

AnimalsCells, CulturedMacrophagesModels, BiologicalMolecular StructureNF-kappaB-Inducing KinaseProtein Serine-Threonine KinasesToll-Like Receptor 4Ultraviolet RaysNF-kappaB-Inducing KinaseProtein Serine-Threonine KinasesToll-Like Receptor 4cage compoundimmune agentsimmunologyreceptorssignal transduction

Identifiers

PMID26097006
PMCPMC4881745

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.